1. Home
  2. TLSA vs KOPN Comparison

TLSA vs KOPN Comparison

Compare TLSA & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.95

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Logo Kopin Corporation

KOPN

Kopin Corporation

N/A

Current Price

$4.50

Market Cap

396.8M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
KOPN
Founded
2013
1984
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
396.8M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
TLSA
KOPN
Price
$0.95
$4.50
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.69
AVG Volume (30 Days)
927.9K
3.5M
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
103.03
EPS
N/A
N/A
Revenue
N/A
$1,530,311.00
Revenue This Year
N/A
$50.07
Revenue Next Year
N/A
$33.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
46.53
52 Week Low
$0.87
$1.81
52 Week High
$2.35
$6.61

Technical Indicators

Market Signals
Indicator
TLSA
KOPN
Relative Strength Index (RSI) 43.42 48.51
Support Level $0.90 $4.20
Resistance Level $1.20 $4.52
Average True Range (ATR) 0.08 0.24
MACD -0.01 -0.07
Stochastic Oscillator 19.32 24.75

Price Performance

Historical Comparison
TLSA
KOPN

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: